“…Although several studies have been published aiming to identify the prevalence of anti-CCP in patients with different rheumatic conditions 2,3,4 , Payet's study was performed in a very large patient cohort and represents, therefore, a relevant information source on this topic. The overall prevalence of anti-CCP in the 723 non-RA patients was rather high compared to other studies 5,6,7 , with a very high proportion of patients with connective tissue disease (CTD) with anti-CCP (17.5%). This allowed the conclusion that, although anti-CCP are rather specific for RA, they are consistently expressed in patients with other rheumatic diseases.…”